share_log

Reported Late Wednesday, HUTCHMED's Tazemetostat For Relapsed/Refractory Follicular Lymphoma Secures NDA Acceptance And Priority Review In China

Reported Late Wednesday, HUTCHMED's Tazemetostat For Relapsed/Refractory Follicular Lymphoma Secures NDA Acceptance And Priority Review In China

據週三晚報導,福修康美藥業的Tazemetostat用於復發/難治性濾泡性淋巴瘤已獲中國新藥申請受理並獲得優先審評。
Benzinga ·  07/05 03:02

Reported Late Wednesday, HUTCHMED's Tazemetostat For Relapsed/Refractory Follicular Lymphoma Secures NDA Acceptance And Priority Review In China

據週三晚報導,福修康美藥業的Tazemetostat用於復發/難治性濾泡性淋巴瘤已獲中國新藥申請受理並獲得優先審評。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論